Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jindan Sheng

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biomolecules|December 23, 2023
Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9Xiaomei Luo, Yingjie Wang, Hao Zhang, et al.
Cancers|August 7, 2021
Targeting <i>RB1</i> Loss in CancersPaing Linn, Susumu Kohno, Jindan Sheng, et al.
Cancer Cell International|October 6, 2023
Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancerJiani Yang, Chao Wang, Yue Zhang, et al.
Phytotherapy Research : PTR|July 9, 2025
Targeting CDK9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian CancerHao Zhang, Xiaomei Luo, Shiwei Li, et al.
BMC Cancer|February 26, 2024
Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancerMeixuan Wu, Sijia Gu, Jiani Yang, et al.
Cell Death and Differentiation|December 18, 2025
Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibitionYuanyuan Zhang, Susumu Kohno, Keqi Gao, et al.
Biomedicines|February 27, 2026
CRISP3, a Potential Tumor Suppressor, Inhibits the Progression of High-Grade Serous Ovarian Carcinoma by Modulating the PI3K/AKT PathwayMingjun Ma, Xiu Tian, Weiwei Cao, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 11, 2023
CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1Mingjun Ma, Chao Wang, Meixuan Wu, et al.
Hepatology (Baltimore, Md.)|May 1, 2021
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination TherapyJindan Sheng, Susumu Kohno, Nobuhiro Okada, et al.
Cell Death & Disease|June 29, 2026
Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasisMingjun Ma, Chao Wang, Yue Zhang, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biomolecules|December 23, 2023
Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9Xiaomei Luo, Yingjie Wang, Hao Zhang, et al.
Cancers|August 7, 2021
Targeting <i>RB1</i> Loss in CancersPaing Linn, Susumu Kohno, Jindan Sheng, et al.
Cancer Cell International|October 6, 2023
Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancerJiani Yang, Chao Wang, Yue Zhang, et al.
Phytotherapy Research : PTR|July 9, 2025
Targeting CDK9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian CancerHao Zhang, Xiaomei Luo, Shiwei Li, et al.
BMC Cancer|February 26, 2024
Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancerMeixuan Wu, Sijia Gu, Jiani Yang, et al.
Cell Death and Differentiation|December 18, 2025
Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibitionYuanyuan Zhang, Susumu Kohno, Keqi Gao, et al.
Biomedicines|February 27, 2026
CRISP3, a Potential Tumor Suppressor, Inhibits the Progression of High-Grade Serous Ovarian Carcinoma by Modulating the PI3K/AKT PathwayMingjun Ma, Xiu Tian, Weiwei Cao, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 11, 2023
CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1Mingjun Ma, Chao Wang, Meixuan Wu, et al.
Hepatology (Baltimore, Md.)|May 1, 2021
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination TherapyJindan Sheng, Susumu Kohno, Nobuhiro Okada, et al.
Cell Death & Disease|June 29, 2026
Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasisMingjun Ma, Chao Wang, Yue Zhang, et al.
Pageof 1